Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Restructuring Costs (2022)

Elicio Therapeutics filings provide 1 years of Restructuring Costs readings, the most recent being $3.1 million for Q4 2022.

  • On a quarterly basis, Restructuring Costs changed N/A to $3.1 million in Q4 2022 year-over-year; TTM through Dec 2022 was $5.9 million, a N/A change, with the full-year FY2022 number at $9.2 million, changed N/A from a year prior.
  • Restructuring Costs hit $3.1 million in Q4 2022 for Elicio Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $3.1 million in Q4 2022 to a low of $2.8 million in Q3 2022.